BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83:517-523. [PMID: 23302714 DOI: 10.1038/ki.2012.401] [Cited by in Crossref: 189] [Cited by in F6Publishing: 143] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Pimazoni-Netto A, Zanella MT. Diabetes guidelines may delay timely adjustments during treatment and might contribute to clinical inertia. Diabetes Technol Ther 2014;16:768-70. [PMID: 24892463 DOI: 10.1089/dia.2014.0092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 Panduru NM, Nistor I, Groop PH, Van Biesen W, Farrington K, Covic A. Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. Nephrol Dial Transplant 2017;32:591-7. [PMID: 28340246 DOI: 10.1093/ndt/gfx021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, Manns BJ, Tonelli M, Hemmelgarn BR. Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. J Am Soc Nephrol 2015;26:2289-302. [PMID: 25556165 DOI: 10.1681/ASN.2014040396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 4.9] [Reference Citation Analysis]
4 Heerspink HJL, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes Obes Metab 2018;20 Suppl 3:14-8. [PMID: 30294954 DOI: 10.1111/dom.13417] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
5 Marshall SM. Preventing kidney failure in people with diabetes. Diabet Med 2014;31:1280-3. [PMID: 24975167 DOI: 10.1111/dme.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Wyatt CM, Cattran DC. Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes? Kidney Int 2016;90:8-10. [PMID: 27312437 DOI: 10.1016/j.kint.2016.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Huri HZ, Lim LP, Lim SK. Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications. Drug Des Devel Ther 2015;9:4355-71. [PMID: 26300627 DOI: 10.2147/DDDT.S85676] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol 2016;8:61-81. [PMID: 27382338 DOI: 10.2147/CPAA.S82008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lee YH, Lee CJ, Lee HS, Choe EY, Lee BW, Ahn CW, Cha BS, Lee HC, Balkau B, Kang ES. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab 2015;41:208-15. [PMID: 25687901 DOI: 10.1016/j.diabet.2015.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
10 Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110:75-81. [PMID: 26361859 DOI: 10.1016/j.diabres.2015.07.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
11 Liao LN, Li CI, Liu CS, Huang CC, Lin WY, Chiang JH, Lin CC, Li TC. Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study. PLoS One 2015;10:e0130828. [PMID: 26098901 DOI: 10.1371/journal.pone.0130828] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Toth-Manikowski S, Atta MG. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. J Diabetes Res 2015;2015:697010. [PMID: 26064987 DOI: 10.1155/2015/697010] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
13 Yasuno T, Maeda T, Tada K, Takahashi K, Ito K, Abe Y, Mukoubara S, Masutani K, Arima H, Nakashima H. Effects of HbA1c on the Development and Progression of Chronic Kidney Disease in Elderly and Middle-Aged Japanese: Iki Epidemiological Study of Atherosclerosis and Chronic Kidney Disease (ISSA-CKD). Intern Med 2020;59:175-80. [PMID: 31554753 DOI: 10.2169/internalmedicine.3242-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Menini S, Iacobini C, Pugliese G, Pesce C. Dietary interventions to contrast the onset and progression of diabetic nephropathy: A critical survey of new data. Crit Rev Food Sci Nutr 2018;58:1671-80. [PMID: 28128635 DOI: 10.1080/10408398.2016.1278355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Adv Ther 2015;32:1029-64. [PMID: 26581749 DOI: 10.1007/s12325-015-0261-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
16 Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:951-64. [PMID: 29079252 DOI: 10.1016/S2213-8587(17)30327-3] [Cited by in Crossref: 137] [Cited by in F6Publishing: 83] [Article Influence: 27.4] [Reference Citation Analysis]
17 Bowry SK, Schoder V, Apel C. An inadvertent but explicable error in calculating number needed to treat for reporting survival data. J Am Soc Nephrol 2014;25:875-6. [PMID: 24722435 DOI: 10.1681/ASN.2014020188] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021;398:786-802. [PMID: 34175022 DOI: 10.1016/S0140-6736(21)00519-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
19 Fogelfeld L, Hart P, Miernik J, Ko J, Calvin D, Tahsin B, Adhami A, Mehrotra R, Fogg L. Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy: Proof-of-concept. Journal of Diabetes and its Complications 2017;31:624-30. [DOI: 10.1016/j.jdiacomp.2016.11.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chang PY, Chien LN, Lin YF, Chiu WT, Chiou HY. Simultaneous control of glycemic, blood pressure, and lipid significantly reduce the risk of renal progression in diabetes patients. Eur J Intern Med 2016;36:87-92. [PMID: 27707566 DOI: 10.1016/j.ejim.2016.09.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Makino Y, Fujita Y, Haneda M. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Curr Opin Nephrol Hypertens. 2015;24:67-73. [PMID: 25415611 DOI: 10.1097/MNH.0000000000000080] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
22 Talbot B, Athavale A, Jha V, Gallagher M. Data Challenges in Addressing Chronic Kidney Disease in Low- and Lower-Middle-Income Countries. Kidney Int Rep 2021;6:1503-12. [PMID: 34169191 DOI: 10.1016/j.ekir.2021.03.901] [Reference Citation Analysis]
23 Chan GC, Tang SC. Diabetic nephropathy: landmark clinical trials and tribulations. Nephrol Dial Transplant 2016;31:359-68. [DOI: 10.1093/ndt/gfu411] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
24 Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Heerspink HJL, van Raalte DH. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. The Lancet Diabetes & Endocrinology 2015;3:367-81. [DOI: 10.1016/s2213-8587(15)00030-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
25 Zagkotsis G, Markou M, Paschou E, Papanikolaou P, Sabanis N. Preventing the development and progression of diabetic kidney disease: Where do we stand? Diabetes Metab Syndr 2018;12:585-90. [PMID: 29602760 DOI: 10.1016/j.dsx.2018.03.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Mbanya JC, Al-sifri S, Abdel-rahim A, Satman I. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes Research and Clinical Practice 2015;109:226-32. [DOI: 10.1016/j.diabres.2015.04.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
27 Amatruda M, Gembillo G, Giuffrida AE, Santoro D, Conti G. The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies. Medicina (Kaunas) 2021;57:868. [PMID: 34577791 DOI: 10.3390/medicina57090868] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lee YH, Kim SH, Kang JM, Heo JH, Kim DJ, Park SH, Sung M, Kim J, Oh J, Yang DH, Lee SH, Lee SY. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol 2019;317:F767-80. [PMID: 31390268 DOI: 10.1152/ajprenal.00565.2018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
29 Bays H. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther 2013;4:195-220. [PMID: 24142577 DOI: 10.1007/s13300-013-0042-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
30 Rodríguez-Gutiérrez R, Montori VM. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes 2016;9:504-12. [PMID: 27553599 DOI: 10.1161/CIRCOUTCOMES.116.002901] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
31 Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, Kahn SE, Marx N, Alexander JH, Zinman B, Pfarr E, Schnaidt S, Meinicke T, von Eynatten M, George JT, Johansen OE, Wanner C;  CARMELINA investigators. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 2020;43:1803-1812. [PMID: 32444457 DOI: 10.2337/dc20-0279] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
32 Kalra S, Unnikrishnan AG, Bantwal G, Das S, Polavarapu NK, Gaurav K. The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India. Diabetes Ther 2021;12:679-95. [PMID: 33511553 DOI: 10.1007/s13300-021-01002-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hanssen NM, Russell N, Cooper ME. Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. Expert Opin Pharmacother 2015;16:1325-33. [PMID: 25912195 DOI: 10.1517/14656566.2015.1041502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Yaqub S, Hamid A, Kashif W, Razzaque MRA, Farooque A, Ahmed B, Ram N. Rapidly progressive diabetic kidney disease: South Asian experience. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-021-00975-z] [Reference Citation Analysis]
35 Teliti M, Cogni G, Sacchi L, Dagliati A, Marini S, Tibollo V, De Cata P, Bellazzi R, Chiovato L. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients. Diab Vasc Dis Res 2018;15:424-32. [PMID: 29911415 DOI: 10.1177/1479164118780808] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
36 Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018;9:CD011798. [PMID: 30246878 DOI: 10.1002/14651858.CD011798.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
37 Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, Wada T. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol 2021. [PMID: 34363037 DOI: 10.1038/s41581-021-00462-y] [Reference Citation Analysis]
38 Ricciardi CA, Gnudi L. Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies. Metabolism 2021;124:154890. [PMID: 34560098 DOI: 10.1016/j.metabol.2021.154890] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
39 Lambers Heerspink HJ, Gansevoort RT. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. Clin J Am Soc Nephrol 2015;10:1079-88. [PMID: 25887073 DOI: 10.2215/CJN.11511114] [Cited by in Crossref: 82] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
40 MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes 2017; 8(5): 172-186 [PMID: 28572879 DOI: 10.4239/wjd.v8.i5.172] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
41 Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013;76:536-50. [PMID: 23802504 DOI: 10.1111/bcp.12195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
42 Quiroga B, Arroyo D, de Arriba G. Present and future in the treatment of diabetic kidney disease. J Diabetes Res 2015;2015:801348. [PMID: 25945357 DOI: 10.1155/2015/801348] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
43 Lim AKh. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361-381. [PMID: 25342915 DOI: 10.2147/ijnrd.s40172] [Cited by in Crossref: 217] [Cited by in F6Publishing: 96] [Article Influence: 27.1] [Reference Citation Analysis]
44 Gala-Błądzińska A, Dumnicka P, Kuśnierz-Cabala B, Rybak K, Drożdż R, Żyłka A, Kuźniewski M. Urinary Neutrophil Gelatinase-Associated Lipocalin Is Complementary to Albuminuria in Diagnosis of Early-Stage Diabetic Kidney Disease in Type 2 Diabetes. Biomed Res Int 2017;2017:4691389. [PMID: 28845433 DOI: 10.1155/2017/4691389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017;46:462-72. [PMID: 29253846 DOI: 10.1159/000484633] [Cited by in Crossref: 154] [Cited by in F6Publishing: 122] [Article Influence: 30.8] [Reference Citation Analysis]
46 Lo C, Toyama T, Hirakawa Y, Jun M, Cass A, Hawley C, Pilmore H, Badve SV, Perkovic V, Zoungas S; Cochrane Kidney and Transplant Group. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011798] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health 2017;2:e000256. [PMID: 29081996 DOI: 10.1136/bmjgh-2016-000256] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
48 MacIsaac RJ, Jerums G, Ekinci EI. Glycemic Control as Primary Prevention for Diabetic Kidney Disease. Adv Chronic Kidney Dis 2018;25:141-8. [PMID: 29580578 DOI: 10.1053/j.ackd.2017.11.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
49 Thomas MC, Paldánius PM, Ayyagari R, Ong SH, Groop PH. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Ther. 2016;7:439-454. [PMID: 27502495 DOI: 10.1007/s13300-016-0189-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
50 van Dieren S, Kengne AP, Chalmers J, Beulens JWJ, Davis TME, Fulcher G, Heller SR, Patel A, Colagiuri S, Hamet P, Mancia G, Marre M, Neal B, Williams B, Peelen LM, van der Schouw YT, Woodward M, Zoungas S. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Diabetes Obes Metab 2014;16:426-32. [DOI: 10.1111/dom.12238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
51 Kannenkeril D, Bosch A, Harazny J, Karg M, Jung S, Ott C, Schmieder RE. Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. Cardiovasc Diabetol 2018;17:128. [PMID: 30231923 DOI: 10.1186/s12933-018-0770-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
52 Vanholder R, Van Laecke S, Glorieux G, Verbeke F, Castillo-Rodriguez E, Ortiz A. Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). Toxins (Basel) 2018;10:E237. [PMID: 29895722 DOI: 10.3390/toxins10060237] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
53 Dobkowski D, Zuber K, Davis J. Updated guidelines for managing chronic kidney disease. JAAPA 2013;26:27-31. [PMID: 24103894 DOI: 10.1097/01.JAA.0000436686.98552.56] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Li L, Ding C, Zou C, Xiong Z, Zhu W, Qian J, Xu M, Zhang A, Liang G. A novel salviadione derivative, compound 15a, attenuates diabetes-induced renal injury by inhibiting NF-κB-mediated inflammatory responses. Toxicol Appl Pharmacol 2020;409:115322. [PMID: 33171189 DOI: 10.1016/j.taap.2020.115322] [Reference Citation Analysis]
55 Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691-704. [PMID: 29937267 DOI: 10.1016/s2213-8587(18)30141-4] [Cited by in Crossref: 320] [Cited by in F6Publishing: 166] [Article Influence: 80.0] [Reference Citation Analysis]
56 Yaseen M, Hassan W, Awad R, Ashqar B, Neyra J, Heister T, Malik O, El-Husseini A. Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era? Kidney Dis (Basel). 2019;5:69-80. [PMID: 31019921 DOI: 10.1159/000495139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
57 Ino J, Kasama E, Kodama M, Sato K, Eizumi H, Kawashima Y, Sekiguchi M, Fujiwara T, Yamazaki A, Suzuki C, Ina S, Okuma A, Nitta K. Multidisciplinary Team Care Delays the Initiation of Renal Replacement Therapy in Diabetes: A Five-year Prospective, Single-center Study. Intern Med 2021;60:2017-26. [PMID: 33518556 DOI: 10.2169/internalmedicine.4927-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Sugiyama T, Goryoda S, Inoue K, Sugiyama-Ihana N, Nishi N. Construction of a simulation model and evaluation of the effect of potential interventions on the incidence of diabetes and initiation of dialysis due to diabetic nephropathy in Japan. BMC Health Serv Res 2017;17:833. [PMID: 29246223 DOI: 10.1186/s12913-017-2784-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
59 Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol 2014;10:325-46. [PMID: 24802062 DOI: 10.1038/nrneph.2014.74] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 14.8] [Reference Citation Analysis]
60 Scheen A, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes & Metabolism 2014;40:176-85. [DOI: 10.1016/j.diabet.2014.03.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
61 Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 2018;117:662-75. [PMID: 29486908 DOI: 10.1016/j.jfma.2018.02.007] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 24.8] [Reference Citation Analysis]
62 Packer M. Concerns about the use of metformin as a first-line agent to slow the progression of chronic kidney disease in diabetes. Diabetes Res Clin Pract 2020;160:108024. [PMID: 31954751 DOI: 10.1016/j.diabres.2020.108024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Andreozzi F, Candido R, Corrao S, Fornengo R, Giancaterini A, Ponzani P, Ponziani MC, Tuccinardi F, Mannino D. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetol Metab Syndr 2020;12:52. [PMID: 32565924 DOI: 10.1186/s13098-020-00559-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
64 Chang PY, Chien LN, Lin YF, Chiou HY, Chiu WT. Nonadherence of Oral Antihyperglycemic Medication Will Increase Risk of End-Stage Renal Disease. Medicine (Baltimore) 2015;94:e2051. [PMID: 26632708 DOI: 10.1097/MD.0000000000002051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
65 Fitchett DH. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice. Eur Endocrinol 2018;14:40-9. [PMID: 30349593 DOI: 10.17925/EE.2018.14.2.40] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014;2:793-800. [PMID: 25043685 DOI: 10.1016/S2213-8587(14)70155-X] [Cited by in Crossref: 100] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
67 Busch M, Nadal J, Schmid M, Paul K, Titze S, Hübner S, Köttgen A, Schultheiss UT, Baid-Agrawal S, Lorenzen J, Schlieper G, Sommerer C, Krane V, Hilge R, Kielstein JT, Kronenberg F, Wanner C, Eckardt KU, Wolf G; GCKD Study Investigators. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrol 2016;17:59. [PMID: 27286816 DOI: 10.1186/s12882-016-0273-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
68 Kang SH, Jung da J, Choi EW, Cho KH, Park JW, Do JY. HbA1c Levels Are Associated with Chronic Kidney Disease in a Non-Diabetic Adult Population: A Nationwide Survey (KNHANES 2011-2013). PLoS One. 2015;10:e0145827. [PMID: 26716684 DOI: 10.1371/journal.pone.0145827] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
69 Herrera-Gómez F, Asensio-González M, González-López A, Álvarez FJ. Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. Front Pharmacol 2017;8:845. [PMID: 29209216 DOI: 10.3389/fphar.2017.00845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Wong MG, Heerspink HJL, Perkovic V. ACCORDION: Ensuring That We Hear the Music Clearly. Clin J Am Soc Nephrol 2018;13:1621-3. [PMID: 30361334 DOI: 10.2215/CJN.11370918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, Reda DJ, Emanuele NV; VADT Study Group. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 2018;61:295-9. [PMID: 29101421 DOI: 10.1007/s00125-017-4473-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 5.4] [Reference Citation Analysis]
72 Feng C, Wu M, Chen Z, Yu X, Nie Z, Zhao Y, Bao B. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol 2019;51:655-69. [PMID: 30830656 DOI: 10.1007/s11255-019-02112-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
73 Scheen AJ. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab. 2019;45:110-121. [PMID: 30477733 DOI: 10.1016/j.diabet.2018.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
74 Cooper ME, Perkovic V, Mcgill JB, Groop P, Wanner C, Rosenstock J, Hehnke U, Woerle H, von Eynatten M. Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. American Journal of Kidney Diseases 2015;66:441-9. [DOI: 10.1053/j.ajkd.2015.03.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 52] [Article Influence: 10.1] [Reference Citation Analysis]
75 Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clin Sci (Lond) 2018;132:489-507. [PMID: 29491123 DOI: 10.1042/CS20180031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
76 Shurraw S, Tonelli M. Intensive glycemic control in type 2 diabetics at high cardiovascular risk: do the benefits justify the risks? Kidney Int. 2013;83:346-348. [PMID: 23446251 DOI: 10.1038/ki.2012.431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Liang S, Cai GY, Chen XM. Clinical and pathological factors associated with progression of diabetic nephropathy. Nephrology (Carlton) 2017;22 Suppl 4:14-9. [PMID: 29155497 DOI: 10.1111/nep.13182] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
78 Jerums G, Ekinci EI, Premaratne E, Baker ST, Panagiotopoulos S, Macisaac RJ. Diabetic nephropathy. In: Defronzo RA, Ferrannini E, Zimmet P, Alberti KGMM, editors. International Textbook of Diabetes Mellitus. Chichester: John Wiley & Sons, Ltd; 2015. pp. 911-25. [DOI: 10.1002/9781118387658.ch62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Mohan V, Cooper ME, Matthews DR, Khunti K. The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. Diabetes Ther 2019;10:1-13. [PMID: 30758834 DOI: 10.1007/s13300-019-0573-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
80 de Borst MH, Navis G. Diabetes: Risks of strict glycaemic control in diabetic nephropathy. Nat Rev Nephrol 2015;11:5-6. [PMID: 25366044 DOI: 10.1038/nrneph.2014.209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
81 De Vriese AS, Fervenza FC. Con: Biomarkers in glomerular diseases: putting the cart before the wheel? Nephrology Dialysis Transplantation 2015;30:885-90. [DOI: 10.1093/ndt/gfv107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
82 Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018;13:1693-702. [PMID: 30361335 DOI: 10.2215/CJN.06200518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
83 Gallagher M, Wong MG, Perkovic V. ALTITUDE: defining a ceiling for blockade of the renin–angiotensin system? The Lancet Diabetes & Endocrinology 2016;4:289-90. [DOI: 10.1016/s2213-8587(15)00518-5] [Reference Citation Analysis]
84 Liu R, Li L, Shao C, Cai H, Wang Z. The Impact of Diabetes on Vascular Disease: Progress from the Perspective of Epidemics and Treatments. J Diabetes Res 2022;2022:1531289. [PMID: 35434140 DOI: 10.1155/2022/1531289] [Reference Citation Analysis]
85 Stephens JW, Brown KE, Min T. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obes Metab 2020;22 Suppl 1:32-45. [PMID: 32267078 DOI: 10.1111/dom.13942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
86 Wu WX, Ren M, Cheng H, Li Y, Qi YQ, Yang C, Yan L. Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study. Endocrine 2014;47:485-92. [PMID: 24452874 DOI: 10.1007/s12020-013-0158-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Adam WR, O'brien RC. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med 2014;31:1032-8. [DOI: 10.1111/dme.12515] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
88 Leiter LA. Latest Evidence on Sulfonylureas: What's New? Diabetes Ther 2020;11:15-22. [PMID: 32323156 DOI: 10.1007/s13300-020-00812-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Chalmers J, Woodward M. Observational analyses from ADVANCE and ADVANCE-ON. Diabetes Obes Metab 2020;22 Suppl 2:19-32. [PMID: 31729126 DOI: 10.1111/dom.13894] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Yun JS, Park YM, Han K, Kim HW, Cha SA, Ahn YB, Ko SH. Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes. Sci Rep 2021;11:4305. [PMID: 33619302 DOI: 10.1038/s41598-021-82838-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Tamura K, Wakui H, Azushima K, Uneda K, Umemura S. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. Hypertens Res 2016;39:396-8. [DOI: 10.1038/hr.2016.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
92 Persson F, Borg R, Rossing P. A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. Ann Transl Med 2021;9:716. [PMID: 33987414 DOI: 10.21037/atm-20-4841] [Reference Citation Analysis]
93 DeFronzo RA, Abdul-Ghani M. Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. Diabetes Spectr 2021;34:225-34. [PMID: 34511848 DOI: 10.2337/ds20-0071] [Reference Citation Analysis]
94 Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther 2022;39:148-64. [PMID: 34846711 DOI: 10.1007/s12325-021-01994-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Molitch ME. Diabetic Kidney Disease: Much Progress, But Still More to Do. Diabetes Spectr 2015;28:154-6. [PMID: 26300605 DOI: 10.2337/diaspect.28.3.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
96 He T, Cooper ME. Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial. Nat Rev Nephrol 2014;10:547-8. [PMID: 25201141 DOI: 10.1038/nrneph.2014.162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
97 Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, Wanner C, Kasiske BL, Wheeler DC, Groop PH; Conference Participants. Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175-1183. [PMID: 27884312 DOI: 10.1016/j.kint.2016.09.010] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 13.6] [Reference Citation Analysis]
98 Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol. 2013;9:713-723. [PMID: 24100266 DOI: 10.1038/nrendo.2013.184] [Cited by in Crossref: 164] [Cited by in F6Publishing: 147] [Article Influence: 18.2] [Reference Citation Analysis]
99 Lu CC, Ma KL, Ruan XZ, Liu BC. The Emerging Roles of Microparticles in Diabetic Nephropathy. Int J Biol Sci 2017;13:1118-25. [PMID: 29104503 DOI: 10.7150/ijbs.21140] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
100 Dekkers IA, Bizino MB, Paiman EHM, Smit JW, Jazet IM, de Vries APJ, Lamb HJ. The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial. J Ren Nutr 2021;31:611-9. [PMID: 33293204 DOI: 10.1053/j.jrn.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Pilla SJ, Shahidzadeh Yazdi Z, Taylor SI. Individualized Glycemic Goals for Older Adults Are a Moving Target. Diabetes Care 2022;45:1029-31. [PMID: 35561130 DOI: 10.2337/dci22-0004] [Reference Citation Analysis]
102 Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: A reappraisal. Diabetes Obes Metab 2020;22:904-15. [PMID: 32009286 DOI: 10.1111/dom.13984] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
103 Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol. 2017;28:368-375. [PMID: 27539604 DOI: 10.1681/asn.2016030278] [Cited by in Crossref: 188] [Cited by in F6Publishing: 87] [Article Influence: 31.3] [Reference Citation Analysis]
104 Coresh J, Levey AS. A Combination of Change in Albuminuria and GFR as a Surrogate End Point for Progression of CKD. Clin J Am Soc Nephrol 2019;14:792-4. [PMID: 31175080 DOI: 10.2215/CJN.04160419] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
105 Chang PY, Chien LN, Bai CH, Lin YF, Chiou HY. Continuity of care with physicians and risk of subsequent hospitalization and end-stage renal disease in newly diagnosed type 2 diabetes mellitus patients. Ther Clin Risk Manag 2018;14:511-21. [PMID: 29559787 DOI: 10.2147/TCRM.S150638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
106 Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS. Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol. 2014;25:2916-2925. [PMID: 24904086 DOI: 10.1681/asn.2013091002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
107 Kiadaliri AA, Gerdtham UG, Eliasson B, Carlsson KS. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. Diabetes Ther 2014;5:591-607. [PMID: 25213800 DOI: 10.1007/s13300-014-0080-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
108 Cheng D, Fei Y, Liu Y, Li J, Chen Y, Wang X, Wang N. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. PLoS One. 2014;9:e111543. [PMID: 25360775 DOI: 10.1371/journal.pone.0111543] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
109 Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig 2017;8:6-18. [PMID: 27181363 DOI: 10.1111/jdi.12533] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
110 Shayman JA. Challenges and opportunities in the development of therapeutics for chronic kidney disease. Transl Res 2015;165:482-7. [PMID: 25218118 DOI: 10.1016/j.trsl.2014.08.002] [Reference Citation Analysis]
111 Chowdhury TA, Srirathan D, Abraham G, Oei EL, Fan SL, Mccafferty K, Yaqoob MM. Could metformin be used in patients with diabetes and advanced chronic kidney disease?: CHOWDHURY et al. Diabetes Obes Metab 2017;19:156-61. [DOI: 10.1111/dom.12799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
112 Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE; AGE-less Study Group. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol 2015;10:759-66. [PMID: 25710801 DOI: 10.2215/CJN.07750814] [Cited by in Crossref: 49] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
113 Molitch ME. Glycemic Control Assessment in the Dialysis Patient: Is Glycated Albumin the Answer? Am J Nephrol 2018;47:18-20. [PMID: 29275401 DOI: 10.1159/000485844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
114 Al-Saleh Y, Sabico S, Al-Furqani A, Jayyousi A, Alromaihi D, Ba-Essa E, Alawadi F, Alkaabi J, Hassanein M, Al-Sifri S, Saleh S, Alessa T, Al-Daghri NM. Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas. Diabetes Ther 2021;12:2115-32. [PMID: 33983614 DOI: 10.1007/s13300-021-01059-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Akhtar M, Taha NM, Nauman A, Mujeeb IB, Al-Nabet ADMH. Diabetic Kidney Disease: Past and Present. Adv Anat Pathol 2020;27:87-97. [PMID: 31876542 DOI: 10.1097/PAP.0000000000000257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
116 Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017;6:CD010137. [PMID: 28594069 DOI: 10.1002/14651858.CD010137.pub2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
117 Mosterd CM, Bjornstad P, van Raalte DH. Nephroprotective effects of GLP-1 receptor agonists: where do we stand? J Nephrol 2020;33:965-75. [PMID: 32356231 DOI: 10.1007/s40620-020-00738-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
118 Doshi SM, Friedman AN. Diagnosis and Management of Type 2 Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2017;12:1366-1373. [PMID: 28280116 DOI: 10.2215/cjn.11111016] [Cited by in Crossref: 77] [Cited by in F6Publishing: 48] [Article Influence: 15.4] [Reference Citation Analysis]
119 Wangnoo S, Shunmugavelu M, Reddy SVB, Negalur V, Godbole S, Dhandhania VK, Krishna N, Gaurav K. Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. Endocrine and Metabolic Science 2021;4:100102. [DOI: 10.1016/j.endmts.2021.100102] [Reference Citation Analysis]
120 Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. Clin J Am Soc Nephrol 2016;11:2177-85. [PMID: 27827311 DOI: 10.2215/CJN.02630316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
121 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S175-84. [PMID: 34964873 DOI: 10.2337/dc22-S011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
122 Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int 2014;86:701-11. [PMID: 25007170 DOI: 10.1038/ki.2014.236] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
123 Batu Demir D, Cooper ME. New strategies to tackle diabetic kidney disease. Curr Opin Nephrol Hypertens 2016;25:348-54. [PMID: 27138228 DOI: 10.1097/MNH.0000000000000234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
124 Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L, Orsi E, Pugliese G; Renal Insufficiency Cardiovascular Events (RIACE) Study Group. Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetol 2015;52:971-81. [PMID: 26155957 DOI: 10.1007/s00592-015-0789-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
125 Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators:., Augusto Vallejos (Argentina)., Richard MacIsaac (Australia)., Guntram Schernthaner (Austria)., Pieter Gillard (Belgium)., Maria Eugenia F. Canziani (Brazil)., Theodora Temelkova-Kurktschiev (Bulgaria)., Ellen Burgess and Sheldon Tobe (Canada)., Fernando González (Chile)., Zhi-Hong Liu (China)., Andrés Ángelo Cadena Bonfanti and Carlos Francisco Jaramillo (Colombia)., Martin Prazny (Czech Republic)., Peter Rossing (Denmark)., Jorma Strand (Finland)., Michel Marre (France)., Roland Schmieder and Christoph Wanner (Germany)., Pantelis A. Sarafidis (Greece)., Juliana Chan (Hong Kong)., László Rosivall (Hungary)., Joseph Eustace (Ireland)., Ehud Grossman and Yoram Yagil (Israel)., Giuseppe Remuzzi (Italy)., Daisuke Koya and Takashi Wada (Japan)., Magdalena Madero Rovalo (Mexico)., Ron Gansevoort and Adriaan Kooy (Netherlands)., Trine Finnes (Norway)., Froilan De Leon (Philippines)., Janusz Gumprecht (Poland)., Fernando Teixeira e Costa (Portugal)., Alexander Dreval (Russia)., Anantharaman Vathsala (Singapore)., Aslam Amod (South Africa)., Sin Gon Kim and Byung Wan Lee (South Korea)., Julio Pascual Santos (Spain)., Bengt-Olov Tengmark (Sweden)., Michel Burnier (Switzerland)., Chien-Te Lee (Taiwan)., Sukit Yamwong (Thailand)., Ramazan Sari (Turkey)., Kieran McCafferty (United Kingdom)., Borys Mankovsky (Ukraine)., Sharon Adler, Linda Fried, Robert Toto, and Mark Williams (United States)., Tran Quang Khanh (Vietnam)., National lead investigators:., Augusto Vallejos (Argentina)., Richard MacIsaac (Australia)., Guntram Schernthaner (Austria)., Pieter Gillard (Belgium)., Maria Eugenia F. Canziani (Brazil)., Theodora Temelkova-Kurktschiev (Bulgaria)., Ellen Burgess and Sheldon Tobe (Canada)., Fernando González (Chile)., Zhi-Hong Liu (China)., Andrés Ángelo Cadena Bonfanti and Carlos Francisco Jaramillo (Colombia)., Martin Prazny (Czech Republic)., Peter Rossing (Denmark)., Jorma Strand (Finland)., Michel Marre (France)., Roland Schmieder and Christoph Wanner (Germany)., Pantelis A. Sarafidis (Greece)., Juliana Chan (Hong Kong)., László Rosivall (Hungary)., Joseph Eustace (Ireland)., Ehud Grossman and Yoram Yagil (Israel)., Giuseppe Remuzzi (Italy)., Daisuke Koya and Takashi Wada (Japan)., Magdalena Madero Rovalo (Mexico)., Ron Gansevoort and Adriaan Kooy (Netherlands)., Trine Finnes (Norway)., Froilan De Leon (Philippines)., Janusz Gumprecht (Poland)., Fernando Teixeira e Costa (Portugal)., Alexander Dreval (Russia)., Anantharaman Vathsala (Singapore)., Aslam Amod (South Africa)., Sin Gon Kim and Byung Wan Lee (South Korea)., Julio Pascual Santos (Spain)., Bengt-Olov Tengmark (Sweden)., Michel Burnier (Switzerland)., Chien-Te Lee (Taiwan)., Sukit Yamwong (Thailand)., Ramazan Sari (Turkey)., Kieran McCafferty (United Kingdom)., Borys Mankovsky (Ukraine)., Sharon Adler, Linda Fried, Robert Toto, and Mark Williams (United States)., Tran Quang Khanh (Vietnam)., Diego Aizenberg., Inés Bartolacci., Diego Besada., Julio Bittar., Mariano Chahin., Alicia Elbert., Elizabeth Gelersztein., Alberto Liberman., Laura Maffei., Federico Pérez Manghi., Hugo Sanabria., Augusto Vallejos., Gloria Viñes., Alfredo Wassermann ., Walter Abhayaratna., Shamasunder Acharya., Elif Ekinci., Darren Lee., Richard MacIsaac., Peak Mann Mah., Craig Nelson., David Packham., Alexia Pape., Simon Roger., Hugo Stephenson., Michael Suranyi., Gary Wittert., Elizabeth Vale., Martin Clodi., Christoph Ebenbichler., Evelyn Fliesser-Görzer., Ursula Hanusch., Michael Krebs., Karl Lhotta., Bernhard Ludvik., Gert Mayer., Peter Neudorfer., Bernhard Paulweber., Rudolf Prager., Wolfgang Preiß., Friedrich Prischl., Gerit-Holger Schernthaner., Harald Sourij., Martin Wiesholzer., Peter Doubel., Wendy Engelen., Pieter Gillard., Jean-Michel Hougardy., Jean-Marie Krzesinski., Bart Maes., Marijn Speeckaert., Koen Stas., Luc van Gaal., Hilde Vanbelleghem., Daniela Antunes., Roberto Botelho., Claudia Brito., Luis Canani., Maria Eugenia Canziani., Maria Cerqueira., Rogerio de Paula., Freddy Eliaschewitz., Carlos Eduardo Figueiredo., Adriana Forti., Miguel Hissa., Maurilo Leite Jr., Emerson Lima., Irene Noronha., Bruno Paolino., Nathalia Paschoalin., Raphael Paschoalin., Roberto Pecoits Filho., Marcio Pereira., Evandro Portes., Dalton Precoma., Rosangela Rea., Miguel Riella., Joao Eduardo Salles., Eduardo Vasconcellos., Sergio Vencio., Emiliya Apostolova., Radostina Boshnyashka., Ghassan Farah., Dimitar Georgiev., Valentina Gushterova., Neli Klyuchkova., Mariya Lucheva., Petya Manova., Dotska Minkova., Boyan Nonchev., Mariyana Pichmanova., Zhulieta Prakova., Rangel Rangelov., Rosen Rashkov., Pavel Stanchev., Bilyana Stoyanovska-Elencheva., Zhivko Tagarev., Theodora Temelkova-Kurktschieva., Svetla Vasileva., Mariana Yoncheva-Mihaylova., Paul Barre., Brian Carlson., James Conway., Serge Cournoyer., Richard Dumas., Sameh Fikry., Richard Goluch., Pavel Hamet., Randolph Hart., Sam Henein., Joanne Liutkus., Francois Madore., Valdemar Martinho., Giuseppe Mazza., Philip McFarlane., Dennis O'Keefe., Sean Peterson., Daniel Schwartz., Daniel Shu., Andrew Steele., Guy Tellier., Karthik Tennankore., Sheldon Tobe., George Tsoukas., Richard Tytus., Louise Vitou., Michael Walsh., Stanley Weisnagel., Igor Wilderman., Jean-Francois Yale., Jorge Cobos., Juan Godoy., Fernando González., Sergio Lobos., Juan Carlos Palma., Juan Carlos Prieto., Eliana Reyes., Carmen Romero., Victor Saavedra., Mario Vega., Ruifang Bu., Hanqing Cai., Nan Chen., Qinkai Chen., Dejun Chen., Jinluo Cheng., Youping Dong., Junwu Dong., Tianjun Guan., Chuanming Hao., Wen Huang., Fangfang Jiang., Minxiang Lei., Ling Li., Zhonghe Li., Xuemei Li., Jingmei Li., Yan Li., Xinling Liang., Bo Liang., Fang Liu., Yinghong Liu., Yuantao Liu., Zhihong Liu., Gang Long., Guoyuan Lu., Weiping Lu., Yibing Lu., Ping Luo., Jianhua Ma., Zhaohui Mo., Jianying Niu., Ai Peng., Jiansong Shen., Feixia Shen., Bingyin Shi., Qing Su., Zhuxing Sun., Shuifu Tang., Nanwei Tong., Hao Wang., Xinjun Wang., Lihua Wang., Guixia Wang., Jianqin Wang., Yangang Wang., Li Wang., Jiali Wei., Tianfeng Wu., Chaoqing Wu., Changying Xing., Fei Xiong., Xudong Xu., Ning Xu., Tiekun Yan., Jinkui Yang., Aiping Yin., Longyi Zeng., Hao Zhang., Yanlin Zhang., Ying Zhang., Wenjing Zhao., Zhiquan Zhao., Hongguang Zheng., Ling Zhong., Dalong Zhu., Yongze Zhuang., Clara Arango., Sandra Barrera., Nelly Beltrán López., Diego Benitez., Guillermo Blanco., Andrés Cadena., Julian Coronel., Carlos Cure., Carlos Durán., Alexander González., Gustavo Guzmán., Eric Hernández., Jaime Ibarra., Carlos Jaramillo., Nicolás Jaramillo., William Kattah., Dora Molina., Gregorio Sánchez., Mónica Terront., Freddy Trujillo., Miguel Urina., Ruben Vargas., Iván Villegas., Hernán Yupanqui., Dino Alferi., Michal Brada., Jiri Brezina., Petr Bucek., Tomas Edelsberger., Drahomira Gulakova., Jitka Hasalova Zapletalova., Olga Hola., Lucie Hornova., Jana Houdova., Helena Hrmova., David Karasek., Sarka Kopecka., Richard Kovar., Eva Krcova., Jiri Kuchar., Vlasta Kutejova., Hana Lubanda., Ivo Matyasek., Magdalena Mokrejsova., Libor Okenka., Martin Prazny., Jiri Pumprla., Pavel Tomanek., Jesper Bech., Jens Faber., Gunnar Gislason., Jørgen Hangaard., Grzegorz Jaroslaw Pacyk., Claus Juhl., Thure Krarup., Morten Lindhardt., Sten Madsbad., Joan Nielsen., Ulrik Pedersen-Bjergaard., Per Poulsen., Ole Rasmussen., Peter Rossing., Karoline Schousboe., Mikko Honkasalo., Kari Humaloja., Kristiina Kananen., Ilkka Kantola., Arvo Koistinen., Pirkko Korsoff., Jorma Lahtela., Sakari Nieminen., Tuomo Nieminen., Karita Sadeharju., Jorma Strand., Sakari Sulosaari., Bertrand Cariou., François Chantrel., Sylvaine Clavel., Christian Combe., Jean-Pierre Fauvel., Karim Gallouj., Didier Gouet., Bruno Guerci., Dominique Guerrot., Maryvonne Hourmant., Alexandre Klein., Christophe Mariat., Michel Marre., Rafik Mesbah., Yannick Le Meur., Arnaud Monier., Olivier Moranne., Pierre Serusclat., Benoit Vendrely., Bruno Verges., Philippe Zaoui., Christoph Axthelm., Andreas Bergmann., Andreas L. Birkenfeld., Hermann Braun., Klaus Busch., Christel Contzen., Stefan Degenhardt., Karl Derwahl., Thomas Giebel., Andreas Hagenow., Hermann Haller., Christoph Hasslacher., Thomas Horacek., Wolfgang Jungmair., Christof Kloos., Thorsten Koch., Thilo Krüger., Anja Mühlfeld., Joachim Müller., Andreas Pfützner., Frank Pistrosch., Ludger Rose., Lars Rump., Volker Schettler., Ingolf Schiefke., Heike Schlichthaar., Bernd Schröppel., Thomas Schürholz., Helena Sigal., Lutz Stemler., Georg Strack., Heidrun Täschner., Nicole Toursarkissian., Diethelm Tschöpe., Achim Ulmer., Markus van der Giet., Christoph Wanner., Bernhard R. Winkelmann., Ioannis Boletis., Erifili Hatziagelaki., Ioannis Ioannidis., Theodora Kounadi., Ioanna Makriniotou., Dorothea Papadopoulou., Aikaterini Papagianni., Ploumis Passadakis., Ioannis Stefanidis., Tai Pang Ip., Paul Lee., On Yan Andrea Luk., Angela Wang., Vincent Yeung., Dora Bajcsi., Peter Danos., Eleonora Harcsa., Szilvia Kazup., Katalin Keltai., Robert Kirschner., Julianna Kiss., Laszlo Kovacs., Beata Lamboy., Botond Literati-Nagy., Margit Mileder., Laszlo Nagy., Ebrahim Noori., Gabor Nyirati., Gizella Petro., Karoly Schneider., Albert Szocs., Szilard Vasas., Krisztina Wudi., Zsolt Zilahi., Marianna Zsom., Joe Eustace., John Holian., Donal Reddan., Yvonne O'Meara., Rosane Abramof Ness., Faiad Adawi., Zaher Armaly., Shaul Atar., Sydney Ben Chetrit., Noa Berar Yanay., Gil Chernin., Mahmud Darawsha., Shai Efrati., Mazen Elias., Evgeny Farber., Mariela Glandt., Ehud Grossman., Majdi Halabi., Khaled Khazim., Idit Liberty., Ofri Mosenzon., Assy Nimer., Doron Schwartz., Julio Wainstein., Yoram Yagil., Robert Zukermann., Aneliya Ilieva Parvanova., Angelo Avogaro., Giovanni Giorgio Battaglia., Maurizio Tiziano Bevilacqua., Enzo Bonora., Carlo Antonio Bossi., Paolo Calabrò., Franco Luigi Cavalot., Roberto Cimino., Mario Gennaro Cozzolino., Salvatore David., Michele Emdin., Enrico Fiaccadori., Paolo Fiorina., Carlo Bruno Giorda., Maria Cristina Gregorini., Gaetano La Manna., Davide Carlo Maggi., Roberta Manti., Giancarla Meregalli., Antonello Pani., Norberto Perico., PierMarco Piatti., Antonio Pisani., Antonio Ettore Pontiroli., Paola Ponzani., Gennaro Santorelli., Domenico Santoro., Renzo Scanziani., Ugo Teatini., Giancarlo Tonolo., Roberto Trevisan., Anna Maria Veronelli., Giorgio Luciano Viviani., Hideo Araki., Osamu Ebisui., Naruhiro Fujita., Ryuichi Furuya., Yoshiyuki Hamamoto., Masahiro Hatazaki., Terumasa Hayashi., Takayuki Higashi., Yoshihide Hirohata., Shuji Horinouchi., Masayuki Inagaki., Masao Ishii., Tamayo Ishiko., Hideaki Jinnouchi., Hidetoshi Kanai., Daisuke Kanda., Hideo Kanehara., Masayuki Kashima., Kiyoe Kato., Takeshi Katsuki., Katsunori Kawamitsu., Satsuki Kawasaki., Fumi Kikuchi., Hidetoshi Kikuchi., Kunihisa Kobayashi., Junko Koide., Miyuki Kubota., Yoshiro Kusano., Hajime Maeda., Sunao Matsubayashi., Kazunari Matsumoto., Yasuto Matsuo., Naoki Matsuoka., Hiroaki Miyaoka., Satoshi Murao., Mikihiro Nakayama., Jun Nakazawa., Takashi Nomiyama., Masayuki Noritake., Takayuki Ogiwara., Hiroshi Ohashi., Hideki Okamoto., Takeshi Osonoi., Nobuhiro Sasaki., Taiji Sekigami., Taro Shibasaki., Hirotaka Shibata., Junji Shinoda., Hiroshi Sobajima., Kazuya Sugitatsu., Toshiyuki Sugiura., Toru Sugiyama., Daisuke Suzuki., Hiroyuki Suzuki., Masaaki Suzuki., Asami Takeda., Asami Tanaka., Seiichi Tanaka., Izumi Tsunematsu., Makoto Ujihara., Daishiro Yamada., Masayo Yamada., Kazuo Yamagata., Ken Yamakawa., Fumiko Yamakawa., Yoshimitsu Yamasaki., Yuko Yambe., Taihei Yanagida., Hidekatsu Yanai., Tetsuyuki Yasuda., Dovile Kriauciuniene., Jurate Lasiene., Antanas Navickas., Lina Radzeviciene., Egle Urbanaviciene., Gediminas Urbonas., Audrone Velaviciene., Rohana Abd Ghani., Nor Azizah Aziz., Li Yuan Lee., Chek Loong Loh., Norhaliza Mohd Ali., Nurain Mohd Noor., Nik Nur Fatnoon Nik Ahmad., Jeyakantha Ratnasingam., Wan Hasnul Halimi Bin Wan Hasan., Wan Mohd Izani Wan Mohamed., Sandro Avila Pardo., Miriam Bastidas Adrian., Alfredo Chew Wong., Jorge Escobedo de la Peña., Guillermo Fanghänel Salmón., Guillermo González Gálvez., Ramiro Gutiérrez Ochoa., Saúl Irizar Santana., Magdalena Madero Rovalo., Gustavo Méndez Machado., Luis Nevarez Ruiz., Denisse Ramos Ibarra., Gabriel Ramos López., Leobardo Sauque Reyna., Gustavo Solache Ortiz., Rafael Valdez Ortiz., Juan Villagordoa Mesa., R.C. Bakker., J.N.M. Barendregt., A.H. Boonstra., Willem Bos., C.B. Brouwer., M. van Buren., Ron Gansevoort., Adriaan Kooy., Marielle Krekels., Ruud J.M. van Leendert., Louis A.G. Lieverse., P.T. Luik., E. Lars Penne., Peter Smak Gregoor., Liffert Vogt., John Baker., Veronica Crawford., Rick Cutfield., Peter Dunn., Jeremy Krebs., Kingsley Nirmalaraj., Russell Scott., Nine Smuts., Erik Eriksen., Trine Finnes., Hans Høivik., Thomas Karlsson., Peter Scott Munk., Maria Radtke., Knut Risberg., Jan Rocke., Leidulv Solnør., Aud-Eldrid Stenehjem., Anne-Beathe Tafjord., Glenda Pamugas., Araceli Panelo., Ronald Perez., Maribel Tanque., Louie Tirador., Michael Villa., Patrycja Butrymowicz., Kazimierz Ciechanowski., Grazyna Cieslik., Edward Franek., Janusz Gumprecht., Michal Hoffmann., Jolanta Krzykowska., Ilona Kurnatowska., Katarzyna Landa., Adam Madrzejewski., Katarzyna Madziarska., Stanislaw Mazur., Piotr Napora., Michal Nowicki., Anna Ocicka-Kozakiewicz., Barbara Rewerska., Teresa Rusicka., Jan Ruxer., Ewa Skokowska., Andrzej Stankiewicz., Tomasz Stompor., Agnieszka Tiuryn-Petrulewicz., Katarzyna Wasilewska., Bogna Wierusz-Wysocka., Renata Wnetrzak-Michalska., Edgar Almeida., Rosa Ballesteros., Carlos Barreto., Idalina Beirao., Rita Birne., Cesar Esteves., Jose Guia., Susana Heitor., Olinda Marques., Pedro Melo., Fernando Nolasco., Amalia Pereira., Cristina Roque., Francisco Rosario., Gil Silva., Ana Silva., Fernando Teixeira e Costa., Ana Vila Lobos., Gregorio Cortes-Maisonet., Amaury Roman-Miranda., Adrian Albota., Cornelia Bala., Hortensia Barbonta., Elena Caceaune., Doina Catrinoui., Ciprian Constantin., Adriana Dumitrescu., Nicoleta Mindrescu., Cristina Mistode., Gabriela Negrisanu., Adriana Onaca., Silvia Paveliu., Ella Pintilei., Lavinia Pop., Amorin Popa., Alexandrina Popescu., Gabriela Radulian., Iosif Szilagyi., Liana Turcu., Georgeta Vacaru., Adrian Vlad., Mikhail Antsiferov., Mikhail Arkhipov., Andrey Babkin., Olga Barbarash., Vitaliy Baranov., Elena Chernyavskaya., Arkadiy Demko., Alexander Dreval., Anton Edin., Polina Ermakova., Valentin Fadeev., Albert Galyavich., Leyla Gaysina., Ivan Gordeev., Irina Ipatko., Marina Kalashnikova., Yuriy Khalimov., Vadim Klimontov., Zhanna Kobalava., Elena Kosmacheva., Natalya Koziolova., Lyudmila Kvitkova Sergey Levashov., Roman Libis., Vyacheslav Marasaev., Natalia Malykh., Vladimir Martynenko., Sofya Malyutina., Imad Merai., Ashot Mkrtumyan., Galina Nechaeva., Nina Petunina., Shamil Palyutin., Leonid Pimenov., Elena Rechkova., Tatyana Rodionova., Oksana Rymar., Ruslan Sardinov., Olga Semenova., Alexander Sherenkov., Oleg Solovev., Elena Smolyarchuk., Leonid Strongin., Olga Ukhanova., Nadezhda Verlan., Natalya Vorokhobina., Davyd Yakhontov., Sergey Yakushin., Elena Zakharova., Alsu Zalevskaya., Olga Zanozina., Elena Zhdanova., Larisa Zhukova., Tatyana Zykova., Chee Fang Sum., Sufi Muhummad Suhail., Ru San Tan., Anantharaman Vathsala., Edmund Wong., Jana Babikova., Ingrid Buganova., Andrej Dzupina., Zuzana Ochodnicka., Dalibor Sosovec., Denisa Spodniakova., Fayzal Ahmed., Aslam Amod., Sindeep Bhana., Larry Distiller., Dirkie Jansen van Rensburg., Mukesh Joshi., Shaifali Joshi., Deepak Lakha., Essack Mitha., Gracjan Podgorski., Naresh Ranjith., Brian Rayner., Paul Rheeder., Mohamed Sarvan., Mary Seeber., Heidi Siebert., Mohammed Tayob., Julien Trokis., Dorothea Urbach., Louis van Zyl., Bum-Soon Choi., Moon Gi Choi., ChoonHee Chung., YouCheol Hwang., ChongHwa Kim., InJoo Kim., JaeHyeon Kim., SinGon Kim., SungGyun Kim., Tae Hee Kim., WooJe Lee., ByungWan Lee., Kang Wook Lee., Kook-Hwan Oh., Ji Eun Oh., Yun Kyu Oh., Dong-Jin Oh., Junbeom Park., Seok Joon Shin., Su-Ah Sung., Jae Myung Yu., Irene Agraz., Francisco Javier Ampudia., Hanane Bouarich., Francesca Calero., Cristina Castro., Secundino Cigarrán Guldris., Josep Cruzado Garrit., Fernando de Álvaro., Josep Galcerán., Olga González Albarrán., Julio Hernández Jaras., Meritxell Ibernón., Francisco Martínez Deben., Ma Dolores Martínez Esteban., José María Pascual Izuel., Judith Martins., Juan Mediavilla., Alfredo Michán., Julio Pascual Santos., Esteban Poch., Manuel Polaina Rusillo., Carlos Sánchez Juan., Rafael Santamaría Olmo., José Julián Segura de la Morena., Alfonso Soto., Maribel Troya., Annette Bruchfeld., Dan Curiac., Ken Eliasson., Malin Frank., Gregor Guron., Olof Hellberg., Margareta Hellgren., Hans Larnefeldt., Carl-Johan Lindholm., Magnus Löndahl., Erik Rein-Hedin., Inga Soveri., Jonas Spaak., Bengt-Olov Tengmark., Daniel Ackermann., Stefan Bilz., Michel Burnier., Christian Forster., Stefan Kalbermatter., Andreas Kistler., Antoinette Pechére-Bertschi., Bernd Schultes., Chiz-Tzung Chang., Cheng-Chieh Hung., Ju-Ying Jiang., Chien-Te Lee., Shuei-Liong Lin., Der-Cherng Tarng., Shih-Te Tu., Mai-Szu Wu., Ming-Ju Wu., Chaicharn Deerochanawong., Chagriya Kitiyakara., Vuddhidej Ophascharoensuk., Chatlert Pongchaiyakul., Bancha Satirapoj., Necmi Eren., Ibrahim Gul., Okan Gulel., Ismail Kocyigit., Abdulbaki Kumbasar., Idris Sahin., Ramazan Sari., Burak Sayin., Talat Tavli., Sedat Ustundag., Yavuz Yenicerioglu., Iryna Bondarets., Volodymyr Botsyurko., Viktoriia Chernikova., Oleksandra Donets., Ivan Fushtey., Mariia Grachova., Anna Isayeva., Dmytro Kogut., Julia Komisarenko., Nonna Kravchun., Kateryna Malyar., Borys Mankovsky., Liliya Martynyuk., Vitaliy Maslyanko., Halyna Myshanych., Larysa Pererva., Nataliia Pertseva., Oleksandr Serhiyenko., Ivan Smirnov., Liubov Sokolova., Vasyl Stryzhak., Maryna Vlasenko., Ahmad AbouSaleh., Jonathan Barratt., Cuong Dang., Hassan Kahal., Adam Kirk., Anne Kilvert., Sui Phi Kon., Kieran McCafferty., Dipesh Patel., Sam Rice., Arutchelvam Vijayaraman., Yuk-ki Wong., Martin Gibson., Mona Wahba., Reza Zaidi., Idalia Acosta., Atoya Adams., Sharon Adler., Dilawar Ajani., Slamat Ali., Radica Alicic., Amer Al-Karadsheh., Sreedhara Alla., D. Allison., Nabil Andrawis., Ahmed Arif., Ahmed Awad., Masoud Azizad., Michael Bahrami., Shweta Bansal., Steven Barag., Ahmad Barakzoy., Mark Barney., Joshua Barzilay., Khalid Bashir., Jose Bautista., Srinivasan Beddhu., Diogo Belo., Sabrina Benjamin., Ramin Berenji., Anuj Bhargava., Jose Birriel., Stephen Brietzke., Frank Brosius., Osvaldo Brusco., Anna Burgner., Robert Busch., Rafael Canadas., Maria Caramori., Jose Cardona., Christopher Case., Humberto Cruz., Ramprasad Dandillaya., Dalia Dawoud., Zia Din., Bradley Dixon., Ankur Doshi., James Drakakis., Mahfouz El Shahawy., Ashraf El-Meanawy., Mohammed El-Shahawy., John Evans., George Fadda., Umar Farooq., Roland Fernando., Raymond Fink., Brian First., David Fitz-Patrick., John Flack., Patrick Fluck., Leon Fogelfeld., Vivian Fonseca., Juan Frias., Claude Galphin., Luis Garcia-Mayol., Gary Goldstein., Edgar Gonzalez., Francisco Gonzalez-Abreu., Ashwini Gore., David Grant., Violet Habwe., Maxine Hamilton., Jamal Hammoud., Stuart Handelsman., Israel Hartman., Glenn Heigerick., Andrew Henry., German Hernandez., Carlos Hernandez-Cassis., Carlos Herrera., Joachim Hertel., Wenyu Huang., Rogelio Iglesias., Ali Iranmanesh., Timothy Jackson., Mahendra Jain., Kenneth Jamerson., Karen Johnson., Eric Judd., Joshua Kaplan., Zeid Kayali., Bobby Khan., Muhammad Khan., Sourabh Kharait., M. Sue Kirkman., Nelson Kopyt., Wayne Kotzker., Csaba Kovesdy., Camil Kreit., Arvind Krishna., Saeed Kronfli., Keung Lee., Derek LeJeune., Brenda Lemus., Carlos Leon-Forero., Douglas Linfert., Henry Lora., Alexander Lurie., Geetha Maddukuri., Alexander Magno., Louis Maletz., Sreedhar Mandayam., Mariana Markell., Ronald Mayfield., Caroline Mbogua., Dierdre McMullen., Carl Meisner., Stephen Minton., Bharat Mocherla., Rajesh Mohandas., Manuel Montero., Moustafa Moustafa., Salil Nadkarni., Samer Nakhle., Jesus Navarro., Nilda Neyra., Romanita Nica., Philip Nicol., Paul Norwood., Visal Numrungroad., Richard O'Donovan., A. Odugbesan., Jorge Paoli-Bruno., Samir Parikh., Rakesh Patel., Aldo Peixoto., Pablo Pergola., Alan Perlman., Karlton Pettis., Roberto Pisoni., Mirela Ponduchi., Jorge Posada., Sharma Prabhakar., Jai Radhakrishnan., Mahboob Rahman., Rupesh Raina., Anjay Rastogi., Efrain Reisin., Marc Rendell., David Robertson., Michael Rocco., Hugo Romeu., Sylvia Rosas., Jack Rosenfeld., Dennis Ross., Jeffrey Rothman., Lance Rudolph., Yusuf Ruhullah., Gary Ruoff., Jeffrey Ryu., Mandeep Sahani., Ramin Sam., Garfield Samuels., William Sanchez., Vladimir Santos., Scott Satko., Sanjeev Saxena., David Scott., Gilberto Seco., Melvin Seek., Harvey Serota., Tariq Shafi., Nauman Shahid., Michael Shanik., Santosh Sharma., Arjun Sinha., James Smelser., Mark Smith., Kyaw Soe., Richard Solomon., Eugene Soroka., Joseph Soufer., Bruce Spinowitz., Leslie Spry., Rosa Suarez., Bala Subramanian., Harold Szerlip., Aparna Tamirisa., Stephen Thomson., Tuan-Huy Tran., Richard Treger., Gretel Trullenque., Thomas Turk., Guillermo Umpierrez., Daniel Urbach., Martin Valdes., Shujauddin Valika., Damaris Vega., Peter Weissman., Adam Whaley-Connell., Jonathan Winston., Jonathan Wise., Alan Wynne., Steven Zeig., Phuong Chu., Lam Van Hoang., Tran Khanh., Nguyen Thi Phi Nga., Pham Nguyen Son., Lan Phuong Tran. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-97. [PMID: 35061867 DOI: 10.2337/dc21-1944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
126 Seidu S, Cos X, Brunton S, Harris S, Jansson S, Mata-cases M, Neijens A, Topsever P, Khunti K. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic Nephropathy: a Tangled Web to Unweave. Cardiovasc Drugs Ther 2017;31:579-92. [PMID: 28956186 DOI: 10.1007/s10557-017-6755-9] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 17.8] [Reference Citation Analysis]
128 Parving H, Persson F, Rossing P. Microalbuminuria: A parameter that has changed diabetes care. Diabetes Research and Clinical Practice 2015;107:1-8. [DOI: 10.1016/j.diabres.2014.10.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 7.9] [Reference Citation Analysis]
129 Kim OY, Lee SM, An WS. Impact of Blood or Erythrocyte Membrane Fatty Acids for Disease Risk Prediction: Focusing on Cardiovascular Disease and Chronic Kidney Disease. Nutrients 2018;10:E1454. [PMID: 30301276 DOI: 10.3390/nu10101454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
130 Mohan V, Khunti K, Chan SP, Filho FF, Tran NQ, Ramaiya K, Joshi S, Mithal A, Mbaye MN, Nicodemus NA Jr, Latt TS, Ji L, Elebrashy IN, Mbanya JC. Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment. Diabetes Ther 2020;11:15-35. [PMID: 31773420 DOI: 10.1007/s13300-019-00733-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
131 Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014;10:88-103. [PMID: 24375052 DOI: 10.1038/nrneph.2013.272] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 13.0] [Reference Citation Analysis]
132 Brownlee M, Aiello LP, Cooper ME, Vinik AI, Plutzky J, Boulton AJ. Complications of Diabetes Mellitus. Williams Textbook of Endocrinology. Elsevier; 2016. pp. 1484-581. [DOI: 10.1016/b978-0-323-29738-7.00033-2] [Cited by in Crossref: 8] [Article Influence: 1.3] [Reference Citation Analysis]
133 Mann JF, Rossing P, Wiȩcek A, Rosivall L, Mark P, Mayer G. Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs? Nephrol Dial Transplant 2015;30 Suppl 4:iv1-5. [PMID: 26209731 DOI: 10.1093/ndt/gfv120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
134 Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia 2018;61:1503-16. [PMID: 29417185 DOI: 10.1007/s00125-018-4547-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
135 Tang SC, Wong AK, Mak SK. Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology. Nephrology (Carlton) 2019;24 Suppl 1:9-26. [PMID: 30900340 DOI: 10.1111/nep.13500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium. Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice? Kidney Int Rep 2019;4:212-21. [PMID: 30775618 DOI: 10.1016/j.ekir.2018.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
137 Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab 2017;19:1155-64. [PMID: 28251792 DOI: 10.1111/dom.12927] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
138 Bittle PA. The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease. Nurse Pract 2017;42:31-8. [PMID: 28225432 DOI: 10.1097/01.NPR.0000512253.40369.ab] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63:S39-S62. [PMID: 24461729 DOI: 10.1053/j.ajkd.2013.10.048] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 19.9] [Reference Citation Analysis]
140 Packer M. Early Worsening of Renal Function After Treatment with Antihyperglycemic Drugs: A Consistent Finding in Large-Scale Trials. Am J Med 2018;131:337-8. [PMID: 29106976 DOI: 10.1016/j.amjmed.2017.10.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, Wang Y. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab 2019;21:1018-26. [PMID: 30565382 DOI: 10.1111/dom.13620] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
142 Osawa T, Fujihara K, Harada M, Yamamoto M, Ishizawa M, Suzuki H, Ishiguro H, Matsubayashi Y, Seida H, Yamanaka N, Tanaka S, Shimano H, Kodama S, Sone H. Higher pulse pressure predicts initiation of dialysis in Japanese patients with diabetes. Diabetes Metab Res Rev 2019;35:e3120. [DOI: 10.1002/dmrr.3120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
143 Cardoso CRL, Leite NC, Salles GC, Ferreira MT, Salles GF. Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia 2018;61:455-65. [PMID: 29063128 DOI: 10.1007/s00125-017-4484-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
144 Araki SI. Comprehensive risk management of diabetic kidney disease in patients with type 2 diabetes mellitus. Diabetol Int 2018;9:100-7. [PMID: 30603356 DOI: 10.1007/s13340-018-0351-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Kwak SH, Park KS. Genetic Studies on Diabetic Microvascular Complications: Focusing on Genome-Wide Association Studies. Endocrinol Metab (Seoul) 2015;30:147-58. [PMID: 26194074 DOI: 10.3803/EnM.2015.30.2.147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
146 Nazarko L. 5. Diabetes and renal function. British Journal of Healthcare Assistants 2017;11:66-71. [DOI: 10.12968/bjha.2017.11.2.66] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2018;136:23-31. [PMID: 29196150 DOI: 10.1016/j.diabres.2017.11.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
148 Trevisan R. The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction. Diabetes Ther 2017;8:1215-26. [PMID: 28983844 DOI: 10.1007/s13300-017-0302-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
149 Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract 2018;143:1-14. [PMID: 29802958 DOI: 10.1016/j.diabres.2018.05.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
150 Penfornis A, Fiquet B, Blicklé JF, Dejager S. Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study. Diabetes Metab Syndr Obes 2015;8:303-13. [PMID: 26170705 DOI: 10.2147/DMSO.S83897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
151 de Borst MH, Navis G. Diabetes: Risks of strict glycaemic control in diabetic nephropathy. Nat Rev Nephrol. 2015;11:5-6. [PMID: 25366044 DOI: 10.1038/nrneph.2014.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
152 Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res. 2016;5:pii: F1000 Faculty Rev-1044. [PMID: 27303648 DOI: 10.12688/f1000research.7693.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
153 Lovrenčić MV, Biljak VR, Blaslov K, Božičević S, Duvnjak LS. Impact of creatinine methodology on glomerular filtration rate estimation in diabetes. World J Diabetes 2017; 8(5): 222-229 [PMID: 28572883 DOI: 10.4239/wjd.v8.i5.222] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
154 Ling W, Huang Y, Huang YM, Fan RR, Sui Y, Zhao HL. Global trend of diabetes mortality attributed to vascular complications, 2000-2016. Cardiovasc Diabetol 2020;19:182. [PMID: 33081808 DOI: 10.1186/s12933-020-01159-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
155 Packer M. Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors. J Am Soc Nephrol. 2020;31:907-919. [PMID: 32276962 DOI: 10.1681/asn.2020010010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
156 Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Prim Care Diabetes 2021;15:31-51. [PMID: 32532635 DOI: 10.1016/j.pcd.2020.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
157 Xie Y, Bowe B, Gibson AK, McGill JB, Yan Y, Maddukuri G, Al-Aly Z. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. Diabetes Care 2020;43:2785-95. [PMID: 32912850 DOI: 10.2337/dc20-1231] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
158 Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. FASEB Bioadv 2019;1:375-88. [PMID: 32123840 DOI: 10.1096/fba.2018-00064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
159 Roy A, Maiti A, Sinha A, Baidya A, Basu AK, Sarkar D, Sanyal D, Biswas D, Maisnam I, Pandit K, Raychaudhuri M, Sengupta N, Chakraborty PP, Mukhopadhyay P, Raychaudhuri P, Sahana PK, Chatterjee P, Bhattacharjee R, Dasgupta R, Saraogi RK, Pal SK, Mukhopadhyay S, Mukhopadhyay S, Goswami S, Chowdhury S, Ghosh S; Working Group of the Endocrine Society of Bengal . Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. Diabetes Ther 2020;11:2791-827. [PMID: 33025397 DOI: 10.1007/s13300-020-00921-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
160 Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2019;7:429-41. [DOI: 10.1016/s2213-8587(19)30086-5] [Cited by in Crossref: 86] [Cited by in F6Publishing: 42] [Article Influence: 28.7] [Reference Citation Analysis]
161 Li J, Tong Y, Zhang Y, Tang L, Lv Q, Zhang F, Hu R, Tong N. Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. Clin Ther 2016;38:372-386.e6. [PMID: 26774276 DOI: 10.1016/j.clinthera.2015.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
162 Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975-1982. [PMID: 25777665 DOI: 10.1016/s0140-6736(14)61601-9] [Cited by in Crossref: 764] [Cited by in F6Publishing: 355] [Article Influence: 109.1] [Reference Citation Analysis]
163 Jung HH. Evaluation of Serum Glucose and Kidney Disease Progression Among Patients With Diabetes. JAMA Netw Open 2021;4:e2127387. [PMID: 34586368 DOI: 10.1001/jamanetworkopen.2021.27387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Hassanein M, Akbar MAJ, Al-Shamiri M, Amir A, Amod A, Chudleigh R, Elhadd T, Heshmat H, Jibani M, Al Saleh YM. Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies. Diabetes Ther 2022;13:1253-80. [PMID: 35679010 DOI: 10.1007/s13300-022-01282-4] [Reference Citation Analysis]
165 Park JI, Bae E, Kim YL, Kang SW, Yang CW, Kim NH, Lee JP, Kim DK, Joo KW, Kim YS, Lee H. Glycemic Control and Mortality in Diabetic Patients Undergoing Dialysis Focusing on the Effects of Age and Dialysis Type: A Prospective Cohort Study in Korea. PLoS One 2015;10:e0136085. [PMID: 26285034 DOI: 10.1371/journal.pone.0136085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
166 Moh AMC, Wang J, Tan C, Ang SF, Ang K, Subramaniam T, Sum CF, Kwan PY, Lee SBM, Tang WE, Lim SC. Association between gain in adiposity and diabetic kidney disease worsening in type 2 diabetes is mediated by deteriorating glycaemic control: A 3-year follow-up analysis. Diabetes Res Clin Pract 2019;157:107812. [PMID: 31401149 DOI: 10.1016/j.diabres.2019.107812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
167 Nilsson LM, Zhang L, Bondar A, Svensson D, Wernerson A, Brismar H, Scott L, Aperia A. Prompt apoptotic response to high glucose in SGLT-expressing renal cells. Am J Physiol Renal Physiol 2019;316:F1078-89. [PMID: 30864838 DOI: 10.1152/ajprenal.00615.2018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]